FDA Approves Bristol Myers Squibb’s Zenbexus for Advanced Multiple Myeloma, Marking Debut of New Drug Class

The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s Zenbexus, an oral treatment for advanced multiple myeloma, marking the first approval of a new class of blood cancer drugs called CELMoDs. This medication works by redirecting a cell’s natural machinery to eliminate cancer-causing proteins, offering a novel therapeutic approach for patients with this aggressive blood cancer. The approval also represents the first time the FDA has used a more sensitive measure of remission in its evaluation process. ## Legal Setback for Bristol Myers in Celgene Acquisition Case In a separate development, a U.S. appeals court ruled that a lower-court judge incorrectly dismissed a $6.7 billion lawsuit against Bristol Myers Squibb. The lawsuit, brought by former Celgene shareholders, alleges that the company deliberately delayed federal approval for three drugs following its $80.3 billion acquisition of Celgene in 2019. The appeals court determined that UMB Bank, acting as a trustee for Celgene shareholders, was entitled to represent them despite procedural errors in its appointment. The case centers on "contingent value rights," which entitled shareholders to an additional $9 per share if Bristol Myers secured timely regulatory approvals for the drugs in question. ## Implications for Blood Cancer Treatment and Shareholder Rights The approval of Zenbexus is a significant milestone in the treatment of multiple myeloma, a cancer that affects plasma cells in the bone marrow. As the first drug in the CELMoDs class, it offers patients a new oral treatment option that may improve outcomes by targeting cancer-causing proteins more effectively. The FDA’s use of a more sensitive remission measure in its approval process could also set a precedent for future evaluations of cancer therapies. Meanwhile, the revival of the lawsuit highlights ongoing legal challenges related to corporate acquisitions and shareholder rights. The case underscores the importance of regulatory transparency and timely drug approvals, particularly in high-stakes mergers where shareholder interests are at stake. The outcome of this litigation could have broader implications for how pharmaceutical companies manage post-acquisition drug development and regulatory strategies.